Quick answers
- What is Travoprost ophthalmic solution used for?
- The FDA-approved label (Travatan Z, Sandoz Inc, January 31, 2025) says: “TRAVATAN Z ® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. TRAVATAN Z is a prostaglandin analog indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Travoprost ophthalmic solution have a boxed warning?
- No. None of the 15 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Travoprost ophthalmic solution?
- The FDA drug shortage list shows “To be discontinued” for a product of this medicine (updated July 7, 2026). Ask your pharmacist about alternatives.
- Has Travoprost ophthalmic solution been recalled?
- FDA enforcement reports list 3 recalls of products of this medicine; the newest started May 25, 2023 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Travoprost ophthalmic solution?
- 14 companies list prescription products of Travoprost ophthalmic solution in the FDA NDC Directory, including Bryant Ranch Prepack, Gland Pharma Limited and Somerset Therapeutics, LLC.
What Travoprost ophthalmic solution is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
TRAVATAN Z ® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. TRAVATAN Z is a prostaglandin analog indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
— FDA label: Travatan Z, Sandoz Inc, effective January 31, 2025. Read the full label on DailyMed →
The FDA has 15 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 15 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Solution/ drops · Solution · Implant |
|---|---|
| Route | Ophthalmic · Intracameral |
| Prescription products | 19 in the FDA NDC Directory |
| Brand names | Travatan Z, Idose Tr, Travoprost Ophthalmic Soluton |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| travoprost 0.04 mg/mL solution | Generic | $8.71–$9.42 per mL 4 packages, lowest to highest |
| travoprost 0.04 mg/mL solution/ drops | Generic | $8.71–$9.42 per mL 8 packages, lowest to highest |
| travoprost 0.04 mg/mL solution/ drops | Brand: Travatan Z | $94.22–$94.33 per mL 2 packages, lowest to highest |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack3 products
- Gland Pharma Limited2 products
- Somerset Therapeutics, LLC2 products
- Alembic Pharmaceuticals Inc.2 products
- Apotex Corp.1 product
- Novartis Pharmaceuticals Corporation1 product
- Alembic Pharmaceuticals Limited1 product
- Mylan Pharmaceuticals Inc.1 product
- Golden State Medical Supply, Inc.1 product
- Glaukos Corporation1 product
- Sandoz Inc1 product
- Glenmark Pharmaceuticals Inc1 product
- Sagent Pharmaceuticals1 product
- Micro Labs Limited1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA021994 TRAVATAN Z | Sandoz | September 21, 2006 | 6, latest October 9, 2025 2025: Labeling · 2020: Labeling · 2017: Labeling |
| NDA218010 IDOSE TR | Glaukos | December 13, 2023 | 2, latest January 27, 2026 2026: Labeling · 2026: Efficacy |
Generic approvals (7)
- ANDA203431Apotex · July 10, 2015
- ANDA205050Mylan · July 7, 2017
- ANDA210458Alembic · December 20, 2019
- ANDA203767Micro Labs · March 19, 2021
- ANDA218159Gland · July 12, 2024
- ANDA217228Somerset Theraps LLC · September 23, 2024
- ANDA214687Alembic · December 17, 2025
Shortage status
To be discontinued · updated July 7, 2026 · first posted July 7, 2026
| Product | Travoprost, Ophthalmic Solution, 0.004%, 5 mL (NDC 0378-9651-50) |
|---|---|
| Company | Mylan Pharmaceuticals Inc., a Viatris Company |
Ask your pharmacist whether your product is affected and what the options are.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
May 25, 2023 · Class II · Terminated · D-0867-2023
Lack of Assurance of Sterility: Tamper Evidence Seal is missing on secondary container.
Travoprost Ophthalmic Solution, USP (Ionic Buffered Solution), 0.004%, Rx only, Manufactured by Apotex Inc., Manufactured by: GSMS Incorporated, Camarillo, CA 93012, a) NDC 51407-731-25 (2.5 mL bottle), b) NDC 51407-731- — Golden State Medical Supply Inc.
-
April 1, 2022 · Class II · Terminated · D-0748-2022
Subpotent Drug and Failed Impurities/Degradation Specifications: low out-of-specification results obtained for assay and high out-of-specification results for related substance impurities/degradation during routine stability testing.
Travoprost Ophthalmic Solution, USP, 0.004%, 2.5 mL bottle, Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 0378-9651-32. — Mylan Pharmaceuticals Inc
-
March 15, 2021 · Class II · Terminated · D-0425-2021
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
TRAVOPROST OPHTHALMIC SOLUTION, USP 0.004% 2.5ML ; NDC/UPC 60505-0593-4; RX; DROPS — Cardinal Health Inc.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 284008, 285032, 2672088, 2672093 |
|---|---|
| SPL set ID of the quoted label | 4b5cffb0-74e0-44e4-8e18-f5d56e9db450 |
| FDA labels (SPL) | 15 |
| FDA applications | NDA021994, NDA218010, 7 ANDA |
| Active ingredients (FDA) | TRAVOPROST |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Travatan Z, Sandoz Inc, effective January 31, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →